Roche secured CE marking for its Cobas Eplex respiratory pathogen panel 3 (RP3), a multiplex molecular assay that detects up to 25 viral and bacterial respiratory targets and offers flexible syndromic sub‑panels for localized needs. The CE approval makes RP3 available across markets accepting the designation, with the company highlighting rapid start‑up and automated reporting. Separately, Diasorin announced a €10 million investment to commercialize the Liaison Nes point‑of‑care PCR system in the U.S., backed by distribution deals with Thermo Fisher and McKesson and prior FDA 510(k) clearance and a CLIA waiver. Together these moves signal renewed vendor focus on rapid, on‑site infectious disease testing capacity in hospitals and clinics.